Addiction / Substance Use Disorders — Deal Benchmarks & Valuation
Market Analysis
Addiction / Substance Use Disorders is one of the most actively transacted indications in neurology licensing. Phase 2 deals for addiction / substance use disorders carry a median total deal value of $2.5B, with upfront payments ranging from $141M to $428M. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones.
Milestone structures for addiction / substance use disorders deals allocate $734M to development milestones, $801M to regulatory milestones, and $689M to commercial milestones. Royalty rates range from 11.7% to 18.7% at the base tier, with tiered escalation reaching 15.7%-22.7% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for addiction / substance use disorders licensing?
What royalty rates are standard for addiction / substance use disorders deals?
How are addiction / substance use disorders deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.